Rexahn Pharmaceuticals Inc.

Rockville, MD, March 11, 2013 – Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company focused on developing first in class therapies for the treatment of cancer, announced today that its new Chief Executive Officer Dr. Peter Suzdak and Chief Financial Officer Ted Jeong are scheduled to make an investor presentation at ROTH [...]

By Peter D. Suzdak, Published: February 17
The Washington Post
[URL]
What has driven me throughout my 25 years in the pharmaceutical industry is the desire to do something that would translate into new therapies to help patients.
When I look back on my career now, I’m fortunate to say that I’ve been able to do that, …..

Published: February 15 | Updated: Sunday, February 17, 12:00 PM
The Washington Post
Click here for more information
Position: Chief executive of Rexahn Pharmaceuticals, a clinical-stage biotechnology company in Rockville.
With a father who ran three businesses in New York City, Peter Suzdak knew as a child that he would wind up in business. After obtaining a doctorate and [...]

Dr. Chang Ahn, CEO of Rexahn, discusses the promising effects of clavulanic acid – the active ingredient in Rexahn’s Phase2 drugs Serdaxin and Zoraxel.

Rexahn announced that it has engaged renowned investment banker Frederick Frank, as an independent consultant, to advise on a range of corporate activities.

Rexahn to Initiate ZoraxelTM Phase II Trial for Erectile Dysfunction

Rockville, MD, April 15, 2010 – Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

Rexahn Pharmaceuticals hopes this will be its big year. With three candidates in various stages of Phase II development and cash projected to last through the first quarter of 2011, Rexahn feels it should be able to land at least one major deal to either co-develop or out-license one its lead programs…

When it comes down to it, my “biotech geek squad” and I have been digging and researching this company since we stumbled upon it weeks ago and frankly, we felt a need to somewhat rush this report out for our readers.